BRCA1 and neoplasm: Given that the pyridostatin/NU‐7441 and pyridostatin/paclitaxel combinations were well‐tolerated in mice (Table 3) and that combination of the three drugs virtually abrogated survival of MDA‐MB‐436 in vitro (Appendix Fig S7C and D), we next established conditions for treating BRCA1‐deficient xenograft tumours with the pyridostatin/NU‐7441/paclitaxel combination.